ARCT News and Press, Arcturus Therapeutics Ltd. From 11/09/20

The news that Pfizer and BioNTech's COVID-19 vaccine is 90% effective in preventing infection appears to be weighing on Arcturus Therapeutics Holdings (ARCT) despite positive preliminary results from a Phase 1/2 study assessing its candidate ARCT-021 in 106 young and old adult volunteers.78 s...

Based on interim Phase 1/2 results, a single 7.5 µg dose of ARCT-021, along with prime-boost regimens are selected to advance into later stage global clinical trials Seroconversion in majority of participants receiving doses in the range of 5 µg to 7.5 µg; Geome...

Arcturus has strong liquidity, and there is no cash problem. Much depends on the success of its COVID-19 vaccine candidate. For us, this looks like a rather risky bet, and we think there are better vaccine plays. For further details see: Arcturus: Flying Due To COVID-19,...

Vallon Pharmaceuticals has filed to raise $17 million in a U.S. IPO. The firm is developing reformulated drug treatment candidates for ADHD and narcolepsy. VALL is related to investor Arcturus Therapeutics, from whom it obtained its core technologies. For further details see...

Arcturus Therapeutics progresses ARCT-810 trial, inks new ARCT-021 collaboration. ALX Oncology provides updates for ALX148 study in myelodysplastic syndrome. Rubius Therapeutics reports positive data for HPV-positive cancers therapy. For further details see: Arcturus Pro...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings (ARCT) completes the first three dose escalation cohorts in its ongoing Phase 1 study with ARCT-810, the messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase ((OTC)) deficiency. The ARCT-810 Phase 1 study is a double blind, placebo-con...

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportu...